IL93756A - Purification of recombinant human interleukin-3 and muteins thereof - Google Patents
Purification of recombinant human interleukin-3 and muteins thereofInfo
- Publication number
- IL93756A IL93756A IL93756A IL9375690A IL93756A IL 93756 A IL93756 A IL 93756A IL 93756 A IL93756 A IL 93756A IL 9375690 A IL9375690 A IL 9375690A IL 93756 A IL93756 A IL 93756A
- Authority
- IL
- Israel
- Prior art keywords
- purification
- muteins
- recombinant human
- human interleukin
- primate
- Prior art date
Links
- 238000000746 purification Methods 0.000 title abstract 2
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 title 1
- 102000000646 Interleukin-3 Human genes 0.000 abstract 1
- 108010002386 Interleukin-3 Proteins 0.000 abstract 1
- 241000288906 Primates Species 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 abstract 1
- 238000004255 ion exchange chromatography Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20041—Use of virus, viral particle or viral elements as a vector
- C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP89200660 | 1989-03-15 | ||
| EP89201967 | 1989-07-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL93756A0 IL93756A0 (en) | 1990-12-23 |
| IL93756A true IL93756A (en) | 1997-06-10 |
Family
ID=26121004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL93756A IL93756A (en) | 1989-03-15 | 1990-03-15 | Purification of recombinant human interleukin-3 and muteins thereof |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0390252B1 (de) |
| JP (1) | JPH03504561A (de) |
| AT (1) | ATE140979T1 (de) |
| AU (1) | AU633891B2 (de) |
| CA (1) | CA2028827A1 (de) |
| DE (1) | DE69027948T2 (de) |
| DK (1) | DK0390252T3 (de) |
| ES (1) | ES2092486T3 (de) |
| FI (1) | FI905593A7 (de) |
| GR (1) | GR3021140T3 (de) |
| HU (1) | HUT56134A (de) |
| IE (1) | IE75344B1 (de) |
| IL (1) | IL93756A (de) |
| NO (1) | NO179252C (de) |
| NZ (1) | NZ232913A (de) |
| PT (1) | PT93458B (de) |
| WO (1) | WO1990010705A2 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5705362A (en) * | 1992-05-25 | 1998-01-06 | Gist-Brocades, N.V. | Modified signal sequences |
| US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
| US5463029A (en) * | 1992-11-23 | 1995-10-31 | Immunex Corporation | Purification of fusion proteins comprising GM-CSF and IL-3 |
| US5738849A (en) * | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
| ATE238421T1 (de) | 1992-11-24 | 2003-05-15 | Searle & Co | Interleukin-3 (il-3)-polypeptide mith mehreren mutationen |
| US6153201A (en) * | 1993-03-09 | 2000-11-28 | University Of Rochester | Oral immunization with papillomavirus virus-like particles |
| US8062642B1 (en) | 1993-03-09 | 2011-11-22 | University Of Rochester | Production of papillomavirus capsid protein and virus-like particles |
| EP1618888B1 (de) * | 1993-03-09 | 2011-01-05 | The University Of Rochester | Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen |
| US5501962A (en) * | 1993-06-21 | 1996-03-26 | G. D. Searle & Co. | Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same |
| US6017523A (en) * | 1995-06-06 | 2000-01-25 | G.D. Searle & Co. | Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides |
| WO1999041382A2 (en) * | 1998-02-17 | 1999-08-19 | Hyseq, Inc. | A novel interleukin-3 and uses thereof |
| US7182947B2 (en) | 1998-02-20 | 2007-02-27 | Medigene Ag | Papillomavirus truncated L1 protein and fusion protein constructs |
| US7494658B2 (en) | 1998-02-20 | 2009-02-24 | Medigene Ag | Papilloma virus truncated L1 protein and fusion protein constructs |
| CA2229955C (en) | 1998-02-20 | 2003-12-09 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
| US20020039584A1 (en) | 1998-02-20 | 2002-04-04 | Medigene Ag | Papilloma virus capsomere vaccine formulations and methods of use |
| US6926897B1 (en) | 1998-03-24 | 2005-08-09 | Medigene Aktiengesellschaft | Medicament for the avoidance or treatment of papillomavirus-specific tumour |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4419446A (en) * | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| GR871029B (en) * | 1986-07-14 | 1987-11-02 | Genetics Inst | Novel osteoinductive factors |
| IL84852A (en) * | 1986-12-16 | 1994-06-24 | Gist Brocades Nv | Molecular cloning and expression of human IL-3 |
| EP0342206A4 (en) * | 1987-01-20 | 1990-09-19 | Immunex Corporation | Human interleukin-3 proteins |
-
1990
- 1990-03-14 NZ NZ232913A patent/NZ232913A/en unknown
- 1990-03-15 WO PCT/NL1990/000030 patent/WO1990010705A2/en not_active Ceased
- 1990-03-15 DK DK90200624.6T patent/DK0390252T3/da active
- 1990-03-15 IL IL93756A patent/IL93756A/xx not_active IP Right Cessation
- 1990-03-15 IE IE93790A patent/IE75344B1/en not_active IP Right Cessation
- 1990-03-15 AT AT90200624T patent/ATE140979T1/de not_active IP Right Cessation
- 1990-03-15 EP EP90200624A patent/EP0390252B1/de not_active Expired - Lifetime
- 1990-03-15 AU AU52644/90A patent/AU633891B2/en not_active Ceased
- 1990-03-15 CA CA002028827A patent/CA2028827A1/en not_active Abandoned
- 1990-03-15 JP JP2504691A patent/JPH03504561A/ja active Pending
- 1990-03-15 FI FI905593A patent/FI905593A7/fi not_active IP Right Cessation
- 1990-03-15 HU HU902850A patent/HUT56134A/hu unknown
- 1990-03-15 DE DE69027948T patent/DE69027948T2/de not_active Expired - Fee Related
- 1990-03-15 PT PT93458A patent/PT93458B/pt active IP Right Grant
- 1990-03-15 ES ES90200624T patent/ES2092486T3/es not_active Expired - Lifetime
- 1990-11-13 NO NO904927A patent/NO179252C/no unknown
-
1996
- 1996-09-25 GR GR960402506T patent/GR3021140T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2092486T3 (es) | 1996-12-01 |
| NO904927L (no) | 1990-11-13 |
| AU5264490A (en) | 1990-10-09 |
| ATE140979T1 (de) | 1996-08-15 |
| IE900937L (en) | 1990-09-15 |
| FI905593A0 (fi) | 1990-11-12 |
| FI905593A7 (fi) | 1990-11-12 |
| AU633891B2 (en) | 1993-02-11 |
| EP0390252B1 (de) | 1996-07-31 |
| IL93756A0 (en) | 1990-12-23 |
| GR3021140T3 (en) | 1996-12-31 |
| HU902850D0 (en) | 1991-02-28 |
| DE69027948D1 (de) | 1996-09-05 |
| JPH03504561A (ja) | 1991-10-09 |
| NZ232913A (en) | 1992-08-26 |
| NO179252B (no) | 1996-05-28 |
| EP0390252A3 (de) | 1991-06-19 |
| CA2028827A1 (en) | 1990-09-16 |
| WO1990010705A3 (en) | 1990-11-01 |
| IE75344B1 (en) | 1997-08-27 |
| PT93458A (pt) | 1990-11-07 |
| PT93458B (pt) | 1997-01-31 |
| DK0390252T3 (da) | 1996-12-09 |
| WO1990010705A2 (en) | 1990-09-20 |
| HUT56134A (en) | 1991-07-29 |
| DE69027948T2 (de) | 1997-01-30 |
| NO179252C (no) | 1996-09-04 |
| EP0390252A2 (de) | 1990-10-03 |
| NO904927D0 (no) | 1990-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL93756A (en) | Purification of recombinant human interleukin-3 and muteins thereof | |
| AU2608292A (en) | Human immunoglobulins produced by recombinant dna techniques | |
| AU6128186A (en) | Purification of hemoglobin and modified hemoglobin by affinity chromatography | |
| GB2238962B (en) | Dual source intravenous adminstration set having an intravenous pump | |
| GR900100621A (en) | Polypeptide analogs of apolipoprotein e diagnostic systems and methods using the analogs | |
| GB2217433B (en) | Single channel needle assembly particularly for biological use | |
| EP0483247A4 (en) | Recombinantly produced human membrane cofactor protein (mcp) | |
| AU6041390A (en) | Cnqx and its analogs as therapeutics for degenerative neural diseases | |
| AU5184190A (en) | Polypeptide having immunological activity for use as diagnostic reagent and/or vaccine | |
| IL80562A0 (en) | Recombinant human lysozyme,its preparation by recombinant dna technology and pharmaceutical compositions containing it | |
| CA2008817A1 (en) | M-csf monoclonal antibodies that recognize a neutralizing conformational epitope | |
| GB2230393B (en) | Injector diagnosis system | |
| AU8328287A (en) | Blood affinity diagnostic method | |
| IT1230744B (it) | Metodo per la determinazione della attivita' funzionale della proteina s nel plasma umano. | |
| AU7172694A (en) | Interleukin-3 (il-3) human/murine hybrid polypeptides | |
| GR890100773A (en) | Method for facing vascular diseases | |
| DE59008693D1 (de) | Gewebs-Plasminogen-Aktivator-Derivat. | |
| AU6387886A (en) | Mitogenic peptides | |
| CS820988A1 (en) | Double-processor control system for acoustic emission's signals processing | |
| GB2220745B (en) | Assay for toxins affecting olfactory enzyme activity | |
| IE891595L (en) | Diagnosis of bovine herpesvirus type 1 infection | |
| IE850411L (en) | Transforming teicoplanin by hydrogenation | |
| AU588552B2 (en) | Apparatus for cryopreparing biological tissue for ultrastructural analysis | |
| CS339888A1 (en) | Mouse lymphocytaric hybridom nf-01 producing antibody against 210 kda protein neurofilament | |
| CS895388A1 (en) | Mouse lymphocyte hybridoma vu cf2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| HP | Change in proprietorship | ||
| RH | Patent void |